Cubist Systematic Strategies LLC lifted its holdings in Inogen, Inc. (NASDAQ:INGN - Free Report) by 109.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 123,242 shares of the medical technology company's stock after purchasing an additional 64,388 shares during the quarter. Cubist Systematic Strategies LLC owned 0.52% of Inogen worth $1,130,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently modified their holdings of INGN. AlphaQuest LLC bought a new position in shares of Inogen in the fourth quarter worth $43,000. Meeder Asset Management Inc. bought a new position in shares of Inogen in the fourth quarter worth $56,000. Integrated Quantitative Investments LLC bought a new position in shares of Inogen in the fourth quarter worth $92,000. Ieq Capital LLC bought a new position in shares of Inogen in the fourth quarter worth $94,000. Finally, Intech Investment Management LLC bought a new position in shares of Inogen in the fourth quarter worth $94,000. Institutional investors own 89.94% of the company's stock.
Inogen Trading Up 5.9%
INGN stock traded up $0.34 during trading hours on Friday, hitting $6.09. 279,171 shares of the stock traded hands, compared to its average volume of 236,930. The stock has a 50-day simple moving average of $6.99 and a 200 day simple moving average of $8.80. Inogen, Inc. has a one year low of $5.70 and a one year high of $13.33. The company has a market cap of $163.74 million, a P/E ratio of -2.71 and a beta of 1.63.
Inogen (NASDAQ:INGN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.27. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. The business had revenue of $82.28 million during the quarter, compared to analysts' expectations of $79.57 million. Analysts forecast that Inogen, Inc. will post -1.73 earnings per share for the current year.
Wall Street Analyst Weigh In
INGN has been the subject of several research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a research note on Wednesday, April 9th. StockNews.com cut Inogen from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus decreased their target price on Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a research note on Thursday, May 8th.
Get Our Latest Analysis on Inogen
About Inogen
(
Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Recommended Stories
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
